3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
2
Hodgkin Disease
2
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mucositis
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Dexamethasone
112
Bortezomib
61
Lenalidomide
49
Cyclophosphamide
49
Calcium Dobesilate
43
pomalidomide
32
Melphalan
31
fludarabine
25
Filgrastim
25
carfilzomib
22
fludarabine phosphate
21
daratumumab
20
Granulocyte Colony-Stimulating Factor
16
Whole-Body Irradiation
15
Antilymphocyte Serum
15
dexamethasone acetate
14
Mycophenolic Acid
14
Thalidomide
13
Tacrolimus
13
Cyclosporine
13
Busulfan
13
Peripheral Blood Stem Cell Transplantation
12
ixazomib
11
dexamethasone 21-phosphate
10
auricularum
10
pembrolizumab
9
Radiotherapy
9
Etoposide
9
belantamab mafodotin
8
Rituximab
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Multiple Myeloma
×
angiotensin I (1-7)
×
Clear all
NCT01121120
2020-12-08
TXA127-PBSC
Tarix Pharmaceuticals
Phase 2
Terminated
75 enrolled